The research partnership will leverage first rate science performed at Yale University along with Evotec’s drug discovery infrastructure and knowledge.
Evotec chief scientific officer Dr Cord Dohrmann said, "Together we want to significantly accelerate this process by removing technical bottlenecks and focusing all efforts on bringing individual projects to highest industrial standards in preparation for development and commercialisation partnerships with Pharma companies."
Both the companies will jointly assess and pursue novel assays, screens and models especially exploratory drug targets and compounds.
Financial details of the deal were not revealed.
Yale’s Office of Cooperative Research managing director Dr Jon Soderstrom said, "Evotec is uniquely suited as a partner as they combine an extremely broad drug discovery platform with fast processes and proven commercialisation skills."